Cipla Ltd (CIPLA):企業の財務・戦略的SWOT分析

◆英語タイトル:Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4818
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Cipla Ltd (CIPLA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cipla Ltd (Cipla) is a global pharmaceutical company which manufactures and distributes branded formulations, generics and active pharmaceutical ingredients (APIs). It offers products for various therapeutic categories including cardiovascular, children’s health, dermatology and cosmetology, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, oncology, neurosciences, ophthalmology, respiratory, osteoporosis, urology and women’s health. The company also operates in consumer healthcare and biosimilar businesses. Cipla is also involved in the manufacture of and metered-dose inhaler devices and spacers and related devices. The company offers its products in India, North America, South Africa and key regulated and emerging markets. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd Key Recent Developments

Jul 13,2018: Cipla to acquire South African drug developer Mirren
Jul 13,2018: Cipla Opens Up To Crowd Sourcing Innovation
Jun 26,2018: Consumers need to understand the risks associated with using medication to combat pain
Jun 12,2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda
May 22,2018: Cipla announces Q4 & FY18 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Cipla Ltd – Key Facts 6
Cipla Ltd – Key Employees 7
Cipla Ltd – Key Employee Biographies 8
Cipla Ltd – Key Operational Employees 9
Cipla Ltd – Major Products and Services 10
Cipla Ltd – History 11
Cipla Ltd – Company Statement 17
Cipla Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 21
Company Overview 21
Cipla Ltd – Business Description 22
Business Segment: New Ventures 22
Overview 22
Performance 22
Business Segment: Pharmaceuticals 22
Overview 22
Performance 22
Geographical Segment: India 22
Performance 22
Geographical Segment: Rest of the World 22
Performance 22
Geographical Segment: South Africa 23
Performance 23
Geographical Segment: United States of America 23
Performance 23
R&D Overview 23
Cipla Ltd – Corporate Strategy 24
Cipla Ltd – SWOT Analysis 25
SWOT Analysis – Overview 25
Cipla Ltd – Strengths 25
Cipla Ltd – Weaknesses 26
Cipla Ltd – Opportunities 27
Cipla Ltd – Threats 28
Cipla Ltd – Key Competitors 29
Section 3 – Company Financial Ratios 30
Financial Ratios – Capital Market Ratios 30
Financial Ratios – Annual Ratios 31
Performance Chart 34
Financial Performance 34
Financial Ratios – Interim Ratios 35
Financial Ratios – Ratio Charts 36
Section 4 – Company’s Lifesciences Financial Deals and Alliances 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38
Cipla Ltd, Recent Deals Summary 39
Section 5 – Company’s Recent Developments 40
Jul 13, 2018: Cipla to acquire South African drug developer Mirren 40
Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 41
Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 43
Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 44
May 22, 2018: Cipla announces Q4 & FY18 results 45
Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 46
Mar 26, 2018: Cipla Launches Authorized Generic Of Aloxi 47
Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 48
Aug 11, 2017: Cipla Announces Q1FY 18 Results 49
Jun 20, 2017: American Cancer Society and Clinton Health Access Initiative Announce Collaborations with Pfizer and Cipla to Increase Access to Lifesaving Cancer Treatment in Africa 50
Section 6 – Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Cipla Ltd, Key Facts 6
Cipla Ltd, Key Employees 7
Cipla Ltd, Key Employee Biographies 8
Cipla Ltd, Key Operational Employees 9
Cipla Ltd, Major Products and Services 10
Cipla Ltd, History 11
Cipla Ltd, Subsidiaries 18
Cipla Ltd, Key Competitors 29
Cipla Ltd, Ratios based on current share price 30
Cipla Ltd, Annual Ratios 31
Cipla Ltd, Annual Ratios (Cont...1) 32
Cipla Ltd, Annual Ratios (Cont...2) 33
Cipla Ltd, Interim Ratios 35
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38
Cipla Ltd, Recent Deals Summary 39
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55

List of Figures
Cipla Ltd, Performance Chart (2014 - 2018) 34
Cipla Ltd, Ratio Charts 36
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 38

★海外企業調査レポート[Cipla Ltd (CIPLA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trina Solar Co Ltd:企業の戦略的SWOT分析
    Trina Solar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cantex Pharmaceuticals Inc (Cantex Pharmaceuticals), formerly ParinGenix Inc is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combi …
  • Vitro, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Taiflex Scientific Co Ltd (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co Ltd (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Prysmian SpA (PRY):電力:M&Aディール及び事業提携情報
    Summary Prysmian SpA (Prysmian) is a provider of cables and systems. It designs, develops, manufactures, supplies, and installs cables for a wide range of applications. The company produces high- and medium voltage cable systems; high and extra high voltage cables; optical fiber, optical cables, opt …
  • Zara Investment (Holding) Co Ltd:戦略・SWOT・企業財務分析
    Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sfinks Polska S.A.
    Sfinks Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Sfinks Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Innovotech Inc (IOT):医療機器:M&Aディール及び事業提携情報
    Summary Innovotech Inc (Innovotech) is a medical device company. The company offers services and solutions to medical, agricultural, and industrial problems caused by microbial biofilms. Its products include InnovoSIL, the antimicrobial agents for coating onto or incorporation into medical devices; …
  • ProPhotonix Limited (STKR):企業の財務・戦略的SWOT分析
    ProPhotonix Limited (STKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Akzo Nobel NV (AKZA):企業の財務・戦略的SWOT分析
    Akzo Nobel NV (AKZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Biosense Webster Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biosense Webster Inc (Biosense Webster), a subsidiary of Johnson & Johnson, is a medical device company that designs, manufactures and markets cardiac arrhythmias products. The company’s products include ablation catheters, diagnostic catheters and access, ultrasound catheters and 3D cardiac …
  • Monster Worldwide Inc:企業の戦略的SWOT分析
    Monster Worldwide Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Golden Valley Mines Ltd. (GZZ):企業の財務・戦略的SWOT分析
    Golden Valley Mines Ltd. (GZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Investment Technology Group, Inc.:企業の戦略・SWOT・財務分析
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Jadranka dd:企業の戦略・SWOT・財務分析
    Jadranka dd - Strategy, SWOT and Corporate Finance Report Summary Jadranka dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Method Products, Inc.:企業の戦略的SWOT分析
    Method Products, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • Veidekke ASA (VEI):企業の財務・戦略的SWOT分析
    Veidekke ASA (VEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • RMB Holdings Ltd. (RMH):企業の財務・戦略的SWOT分析
    RMB Holdings Ltd. (RMH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆